Login Register Cart 0
Generic placeholder image

Current Nutrition & Food Science

Editor-in-Chief

ISSN (Print): 1573-4013
ISSN (Online): 2212-3881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Vitamin K as a Simple but Efficient Add-on to the Current Treatment Regime of COVID-19: A Narrative Review

Author(s): Souparnika Sreelatha*, Nayana Devang and Aradhana Marathe

Volume 18, Issue 7, 2022

Published on: 10 May, 2022

Page: [610 - 617] Pages: 8

DOI: 10.2174/1573401318666220405134759

Price: $65

Abstract

Background: Intravascular thrombosis and pulmonary fibrosis in COVID-19 patients with pneumonia are significantly associated with the severity of the disease. Vitamin K is known to balance the coagulation mechanisms and also prevent calcification and fibrosis of the extrahepatic soft tissues. This narrative review focuses on the role of vitamin K as a linking factor for thrombotic as well as pulmonary complications of COVID-19.

Materials and Methods: Article search was performed in databases of WHO, PubMed, Scopus and Clinical Trial Registry using appropriate keywords. Original articles included very few observational studies which showed a reduced level of vitamin K as well as activated extrahepatic vitamin K Dependent Proteins (VKDP) in COVID-19 patients when compared to healthy controls. Chronic treatment with vitamin K Antagonists did not reduce the risk of in-hospital death. Docking study was performed using Swiss dock, and it demonstrated a significant interaction between menaquinone and SARS-CoV-2 main protease (SARS-CoV-2 Mpro).

Results and Discussion: Deficiency of vitamin K in COVID-19 can be due to excessive use of antagonists or defective ingestion or absorption. This triggers an imbalance in the normal coagulation- anticoagulation mechanism by channeling the available vitamin K to the liver, thereby causing a deficiency of the same in extrahepatic tissues, thus finally leading to thrombosis. This also prevents carboxylation and activation of extrahepatic VKDP required to prevent the calcification of soft tissues, thus leading to lung fibrosis.

Conclusion: Supplementation of vitamin K should be considered as a potentially modifiable risk factor in severe COVID-19. Randomized control trials are highly recommended to provide clearer evidence on the same.

Keywords: Vitamin K, COVID-19, Thromboembolism, Pulmonary fibrosis, Vitamin K Supplementation, Vitamin K Dependent Proteins.

« Previous Next »
Graphical Abstract

[1]
Mirzaie A, Halaji M, Dehkordi FS, Ranjbar R, Noorbazargan H. A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19). Complement Ther Clin Pract 2020; 40: 101214.
[http://dx.doi.org/10.1016/j.ctcp.2020.101214] [PMID: 32891290]
[2]
Halaji M, Farahani A, Ranjbar R, Heiat M, Dehkordi FS. Emerging coronaviruses: First SARS, second MERS and third SARS-CoV-2: Epidemiological updates of COVID-19. Infez Med 2020; 28(Suppl. 1): 6-17.
[PMID: 32532933]
[3]
Sheikhshahrokh A, Ranjbar R, Saeidi E, et al. Frontier therapeutics and vaccine strategies for sars-cov-2 (COVID-19): A review. Iran J Public Health 2020; 49(Suppl. 1): 18-29.
[http://dx.doi.org/10.18502/ijph.v49iS1.3666] [PMID: 34268202]
[4]
Ranjbar R, Mahmoodzadeh H, Safarpoor Dehkordi F. A review on biochemical and immunological biomarkers used for laboratory diagnosis of SARS-CoV-2 (COVID-19). Open Microbiol J 2020; 14(1): 290-6.
[http://dx.doi.org/10.2174/1874434602014010290]
[5]
Léonard-Lorant I, Delabranche X, Séverac F, et al. Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to d-dimer levels. Radiology 2020; 296(3): E189-91.
[http://dx.doi.org/10.1148/radiol.2020201561] [PMID: 32324102]
[6]
Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18(6): 1421-4.
[http://dx.doi.org/10.1111/jth.14830] [PMID: 32271988]
[7]
Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-7.
[http://dx.doi.org/10.1016/j.thromres.2020.04.013] [PMID: 32291094]
[8]
Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18(8): 1995-2002.
[http://dx.doi.org/10.1111/jth.14888] [PMID: 32369666]
[9]
Price LC, McCabe C, Garfield B, Wort SJ. Thrombosis and COVID-19 pneumonia: the clot thickens! Eur Respir J 2020; 56(1): 2001608.
[http://dx.doi.org/10.1183/13993003.01608-2020] [PMID: 32554532]
[10]
Linneberg A, Kampmann FB, Israelsen SB, et al. The association of low vitamin K status with mortality in a cohort of 138 hospitalized patients with COVID-19. Nutrients 2021; 13(6): 1985.
[http://dx.doi.org/10.3390/nu13061985] [PMID: 34207745]
[11]
Simes DC, Viegas CSB, Araújo N, Marreiros C. Vitamin K as a diet supplement with impact in human health: current evidence in age-related diseases. Nutrients 2020; 12(1): 138.
[http://dx.doi.org/10.3390/nu12010138] [PMID: 31947821]
[12]
Berenjian A, Sarabadani Z. How menaquinone-7 deficiency influences mortality and morbidity among COVID-19 patients. Biocatal Agric Biotechnol 2020; 29: 101792.
[http://dx.doi.org/10.1016/j.bcab.2020.101792] [PMID: 32952745]
[13]
Dofferhoff ASM, Piscaer I, Schurgers LJ, et al. Reduced vitamin K status as a potentially modifiable risk factor of severe COVID-19. Clin Infect Dis 2020; 1-8.
[14]
Covino M, De Matteis G, Della D, et al. Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients? Aging Clin Exp Res 2021; 33(8): 2335-43.
[http://dx.doi.org/10.1007/s40520-021-01924-w] [PMID: 34216379]
[15]
Wang R, Hu Q, Wang H, et al. Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CLpro. Int J Biol Macromol 2021; 183: 182-92.
[http://dx.doi.org/10.1016/j.ijbiomac.2021.04.129] [PMID: 33901557]
[16]
Desai AP, Dirajlal-Fargo S, Durieux JC, Tribout H, Labbato D, McComsey GA. Vitamin K & D deficiencies are independently associated with COVID-19 disease severity. Open Forum Infect Dis 2021; 8(10): ofab408.
[http://dx.doi.org/10.1093/ofid/ofab408]
[17]
Deschasaux-Tanguy M, Srour B, Bourhis L, et al. Nutritional risk factors for SARS-CoV-2 infection: A prospective study within the NutriNet-Santé cohort. BMC Med 2021; 19(1): 290.
[http://dx.doi.org/10.1186/s12916-021-02168-1] [PMID: 34844606]
[18]
Zou JN, Sun L, Wang BR, et al. The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT. PLoS One 2021; 16(3): e0248957.
[http://dx.doi.org/10.1371/journal.pone.0248957] [PMID: 33755708]
[19]
Kumano O, Akatsuchi K, Amiral J. Updates on anticoagulation and laboratory tools for therapy monitoring of heparin, vitamin K antagonists and direct oral anticoagulants. Biomedicines 2021; 9(3): 264.
[http://dx.doi.org/10.3390/biomedicines9030264] [PMID: 33799956]
[20]
Schurgers LJ, Spronk HM. Differential cellular effects of old and new oral anticoagulants: Consequences to the genesis and progression of atherosclerosis. Thromb Haemost 2014; 112(5): 909-17.
[PMID: 25298033]
[21]
Rosing J, Maurissen LF, Tchaikovski SN, Tans G, Hackeng TM. Protein S is a cofactor for tissue factor pathway inhibitor. Thromb Res 2008; 122(Suppl. 1): S60-3.
[http://dx.doi.org/10.1016/S0049-3848(08)70021-5] [PMID: 18691502]
[22]
Piscaer I, Wouters EFM, Vermeer C, Janssens W, Franssen FME, Janssen R. Vitamin K deficiency: The linking pin between COPD and cardiovascular diseases? Respir Res 2017; 18(1): 189.
[http://dx.doi.org/10.1186/s12931-017-0673-z] [PMID: 29132356]
[23]
Lee JS, Basalyga DM, Simionescu A, Isenburg JC, Simionescu DT, Vyavahare NR. Elastin calcification in the rat subdermal model is accompanied by up-regulation of degradative and osteogenic cellular responses. Am J Pathol 2006; 168(2): 490-8.
[http://dx.doi.org/10.2353/ajpath.2006.050338] [PMID: 16436663]
[24]
Willems BA, Vermeer C, Reutelingsperger CP, Schurgers LJ. The realm of vitamin K dependent proteins: Shifting from coagulation toward calcification. Mol Nutr Food Res 2014; 58(8): 1620-35.
[http://dx.doi.org/10.1002/mnfr.201300743] [PMID: 24668744]
[25]
Janssen R, Visser MPJ, Dofferhoff ASM, Vermeer C, Janssens W, Walk J. Vitamin K metabolism as the potential missing link between lung damage and thromboembolism in Coronavirus disease 2019. Br J Nutr 2021; 126(2): 191-8.
[http://dx.doi.org/10.1017/S0007114520003979] [PMID: 33023681]
[26]
Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action. Br J Haematol 2020; 189(5): 846-7.
[http://dx.doi.org/10.1111/bjh.16727] [PMID: 32304577]
[27]
Trevisan C, Miconi L, Barbierato E, et al. Labile PT-INR in a Covid-19 patient under long-term vitamin k antagonist therapy: A case report. SN Compr Clin Med 2020; 2(9): 1-3.
[http://dx.doi.org/10.1007/s42399-020-00460-4] [PMID: 32839751]
[28]
Buenen AG, Sinkeldam M, Maas ML, Verdonschot M, Wever PC. Prior use of anticoagulation is associated with a better survival in COVID-19. J Thromb Thrombolysis 2021; 52(4): 1207-11.
[http://dx.doi.org/10.1007/s11239-021-02486-4] [PMID: 34061283]
[29]
Camilleri E, van Rein N, van der Meer FJM, Nierman MC, Lijfering WM, Cannegieter SC. Stability of vitamin K antagonist anticoagulation after COVID-19 diagnosis. Res Pract Thromb Haemost 2021; 5(7): e12597.
[http://dx.doi.org/10.1002/rth2.12597] [PMID: 34667920]
[30]
Schurgers LJ, Shearer MJ, Hamulyák K, Stöcklin E, Vermeer C. Effect of vitamin K intake on the stability of oral anticoagulant treatment: Dose-response relationships in healthy subjects. Blood 2004; 104(9): 2682-9.
[http://dx.doi.org/10.1182/blood-2004-04-1525] [PMID: 15231565]
[31]
Morales A, Rojo Rello S, Cristóbal H, et al. Growth arrest-specific factor 6 (GAS6) is increased in COVID-19 patients and predicts clinical outcome. Biomedicines 2021; 9(4): 335.
[http://dx.doi.org/10.3390/biomedicines9040335] [PMID: 33810394]
[32]
Yan Y, Yang Y, Wang F, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care 2020; 8(1): e001343.
[http://dx.doi.org/10.1136/bmjdrc-2020-001343] [PMID: 32345579]
[33]
Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): Anti-inflammatory strategies. J Biol Regul Homeost Agents 2020; 34(2): 327-31.
[PMID: 32171193]
[34]
Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020; 146(1): 110-8.
[http://dx.doi.org/10.1016/j.jaci.2020.04.006] [PMID: 32294485]
[35]
Smolders J, van den Ouweland J, Geven C, Pickkers P, Kox M. Letter to the Editor: Vitamin D deficiency in COVID-19: Mixing up cause and consequence. Metabolism In: 2021. 115: 154434.
[36]
Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020; 2(8): 1-8.
[http://dx.doi.org/10.1007/s42399-020-00363-4] [PMID: 32838147]
[37]
Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. BMJ 2020; 369: m1966.
[http://dx.doi.org/10.1136/bmj.m1966] [PMID: 32444366]
[38]
Jespersen T, Møllehave LT, Thuesen BH, et al. Uncarboxylated matrix Gla-protein: A biomarker of vitamin K status and cardiovascular risk. Clin Biochem 2020; 83: 49-56.
[http://dx.doi.org/10.1016/j.clinbiochem.2020.05.005] [PMID: 32422228]
[39]
Thomsen SB, Rathcke CN, Zerahn B, Vestergaard H. Increased levels of the calcification marker matrix Gla Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diabetes and ischemic heart disease. Cardiovasc Diabetol 2010; 9(1): 86.
[http://dx.doi.org/10.1186/1475-2840-9-86] [PMID: 21143859]
[40]
Wei FF, Trenson S, Thijs L, et al. Desphospho-uncarboxylated matrix Gla protein is a novel circulating biomarker predicting deterioration of renal function in the general population. Nephrol Dial Transplant 2018; 33(7): 1122-8.
[http://dx.doi.org/10.1093/ndt/gfx258] [PMID: 28992263]
[41]
Holcomb D, Alexaki A, Hernandez N, et al. Gene variants of coagulation related proteins that interact with SARS-CoV-2. PLOS Comput Biol 2021; 17(3): e1008805.
[http://dx.doi.org/10.1371/journal.pcbi.1008805] [PMID: 33730015]
[42]
Janssen R, Walk J. Vitamin K epoxide reductase complex subunit 1 (VKORC1) gene polymorphism as determinant of differences in Covid-19-related disease severity. Med Hypotheses 2020; 144: 110218.
[http://dx.doi.org/10.1016/j.mehy.2020.110218] [PMID: 33254525]
[43]
Pfefferle S, Schöpf J, Kögl M, et al. The SARS-coronavirus-host interactome: Identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog 2011; 7(10): e1002331.
[http://dx.doi.org/10.1371/journal.ppat.1002331] [PMID: 22046132]
[44]
Goddek S. Vitamin D3 and K2 and their potential contribution to reducing the COVID-19 mortality rate. Int J Infect Dis 2020; 99: 286-90.
[http://dx.doi.org/10.1016/j.ijid.2020.07.080] [PMID: 32768697]
[45]
Nguyen DD, Gao K, Chen J, Wang R, Wei GW. Unveiling the molecular mechanism of SARS-CoV-2 main protease inhibition from 137 crystal structures using algebraic topology and deep learning. Chem Sci (Camb) 2020; 11(44): 12036-46.
[http://dx.doi.org/10.1039/D0SC04641H] [PMID: 34123218]

Rights & Permissions Print Cite
Article Metrics
15
1
© 2024 Bentham Science Publishers | Privacy Policy